Objective: Chemotherapy side-effects can be substantial. There is increasing recognition that some oestrogen receptor positive (ER +ve), human epidermal growth factor receptor 2 negative (HER2 −ve) patients with breast cancer derive no benefit from chemotherapy and experience only iatrogenic harm. Gene expression profiling tests help refine recurrence risk and likely chemotherapy benefit. EndoPredict® is one such test, which classifies risks of distant recurrence as low or high in patients treated with surgery and adjuvant endocrine therapy alone. We compared treatment decisions pre-test and post-test results, patients' anxiety, decisional conflict, and oncologists' confidence about the decisions made. Results: Sixty-seven percent patients initially prescribed endocrine alone with high risk result upgraded to endocrine+chemotherapy (E + C); 83% prescribed E + C and had low risk scores, downgraded to E. None of 46 patients initially favouring E alone, who were low risk, changed decisions. Oncologists' confidence about decisions was significantly increased following the results (P = 0.002). Patients with downgraded treatment decisions had significantly lower anxiety scores (P = 0.045); those upgraded had increased scores (P = 0.001). Overall decisional conflict and uncertainty fell significantly post-test (P < 0.022).
| BACKGROUND
Balancing the harms as well as the putative benefits of all breast cancer treatments is a vital component of decision-making. Side-effects of chemotherapy such as hair loss, fatigue, nausea, and vomiting can be substantial and exert a deleterious impact on body image and quality of life. 1 Coping with some of these side-effects may be more tolerable if patients feel that the risks of recurrence are significantly reduced.
Conversely over-treatment with drugs that make little or no difference to a patient's recurrence risk needs to be avoided. Establishing the risk of early and late stage recurrence in early breast cancer can be capricious. Historically, features including tumour size, histological grade, type, nodal involvement, and lympho-vascular invasion were seen as useful prognostic indicators; these characteristics, together with biomarkers such as oestrogen receptor/progesterone receptor (ER/PR) and human epidermal growth factor receptor (HER) status, help to determine which patients have a greater risk and therefore potentially better outcome with and without adjuvant therapy. 2 As further data emerge regarding the longer term risks of distant recurrence, certain tests may also help to determine how long patients should be encouraged to continue with endocrine therapy.
More recent biomarker research has focused on the development of prognostic and ultimately predictive tests to ensure that systemic endocrine and/or chemotherapy is only given to those patients with tumour characteristics that might make response more likely and In this study, we compared pre and post EndoPredict test results: adjuvant treatment decisions, the patients' anxiety, their decisional conflict, and oncologists' confidence about decisions made.
| METHODS
A non-randomised prospective cohort study measuring decision-making for adjuvant chemotherapy before and after EndoPredict testing.
Study objectives included: 
| Recruitment
Post-operatively prospective patients were discussed by their treating 
| Assessments
The DCS assesses an individual's uncertainty when choosing between options, and factors contributing to that including feeling uninformed and unsupported. Decisional conflict can also be affected by issues such as pressure from others, lack of clarity about options, and preexisting or unrealistic expectations. All of these are areas that might be experienced by women considering adjuvant therapy. The DCS is composed of 16-items with a 5-point Likert categorical response scale:
"strongly agree", "agree", "neither agree nor disagree", "disagree", and 
| Statistical methods
Standard scoring rules were followed for the DCS and STAI. Means and change scores were calculated and paired t-tests or Chi2 statistics used as appropriate to determine significance of these between initial and post EndoPredict test decisions.
Doctors' confidence pre-test and post-test was compared using Chi2 statistics.
Pre and post-test means and score changes for the STAI and DCS scales were compared using T-tests.
All scores were based on raw data, without imputation. DCS responses were originally based on a 1 to 5 scale where 1 = strongly agree and 5 = strongly disagree, and converted to percentages. DCS sub-scales were calculated where there were 2 or more responses.
Total DCS scores were calculated where there were 2 or more responses for all sub-scales. STAI scores were calculated where there were fewer than 2/20 missing responses.
| RESULTS
One hundred and fifty-one patients were enrolled into the study of whom 149 were eligible and completed the study. (2 patients did not have EndoPredict test data available for evaluation for technical reasons). Table 1 shows patient characteristics.
The median Nottingham Prognostic Index was 3.76. Of 149 tested tumours, 99 had no evidence of nodal metastases, 29 had macrometastases, and a further 21 micrometastases alone. All patients were ER positive and Her-2 negative as entry criteria for the trial.
| EndoPredict test results
The initial shared decision for 88 patients (59.1%) was endocrine treatment alone and for 61(40.9%) endocrine therapy plus chemotherapy. 
| Patients' anxiety
STAI state anxiety scores were stable in patients with unchanged decisions for endocrine alone or endocrine plus chemotherapy. Those patients whose therapy was downgraded (27/61) had significantly lower state anxiety scores (P = 0.045) whereas those whose treatment was upgraded had increased scores (P = 0.001). There was no significant difference in state scores pre-post test in those who had high or low trait anxiety. Table 3 shows the total scores and the 5 subscale scores on the DCS.
| Decisional conflict
Post-test patients were less uncertain, more informed, and felt more effective. Decisional conflict was reduced significantly (P = 0.022), but this was influenced by those patients whose treatment remained unchanged (94/149). Table 4 shows that patients with unchanged decisions had significantly lower uncertainty scores (mean change 4.78, P = 0.001). In those for whom treatment was downgraded, it fell slightly ((27/149) mean change 1.87) and uncertainty increased (mean change −1.07)
where treatment was upgraded (28/149).
| DISCUSSION
The appropriate use of gene-expression profiling tests has the potential for maximising benefit and reducing iatrogenic harm. This study showed that EPClin test results increased oncologists' and patients' decision-making confidence. The matching of risk scores with therapy decisions was mainly improved although some post-test decisions need further examination. Our results are similar to other prospective decision impact studies using 21 gene assays where adjuvant treatment decisions changed in at least 25% of patients and decisional conflict decreased, too. 
| Clinical implications
There is recognition that not all women with early breast cancer need or benefit from adjuvant chemotherapy. Many lay populations feel that in the context of life-threatening disease more treatment must be better. Gene expression profiling tests provide a risk of recurrence score that should enable wiser decision-making. This study showed that in general the receipt of risk scores helped doctors feel more confident about decisions. Patients felt less decisional conflict and for those who had treatment decisions downgraded from chemotherapy to no chemotherapy, anxiety significantly decreased.
| Study limitations
This was a small study and had a few surprising findings as not all decisions appeared rational. Further work needs to be done exploring It would be interesting to ascertain why some patients persisted with chemotherapy despite having low risk scores. Finally, more information regarding the socio-educational background and understanding of recurrence might be helpful in future research.
| CONCLUSION
As discussions about the logic and rationale behind different treatment recommendations for breast cancer have become increasingly complex, clinicians need an increased repertoire of communication skills to explain risks and benefits easily, or patients are probably not making informed choices about options. 
